SYNERGISM FROM COMBINED IMMUNOLOGIC AND PHARMACOLOGIC INHIBITION OF HER2 IN VIVO

The monoclonal antibody trastuzumab and the EGFR/HER2 tyrosine kinase inhibitor lapatinib improve the clinical outcome of patients with HER2-overexpressing breast cancer. However, the majority of metastatic cancers will eventually progress suggesting the need for other therapies. Because HER2 overex...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Morse, Michael A., Wei, Junping, Hartman, Zachary, Xia, Wenle, Ren, Xiu-Rong, Lei, Gangjun, Barry, William T., Osada, Takuya, Hobeika, Amy C., Peplinski, Sharon, Jiang, Haixiang, Devi, Gayathri R., Chen, Wei, Spector, Neil, Amalfitano, Andrea, Lyerly, H. Kim, Clay, Timothy M.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2010
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC2856803/
https://ncbi.nlm.nih.gov/pubmed/19856307
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ijc.24995
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia